US Chloroform Market Holds Steady as Balanced Fundamentals Limit Price Movement

Chloroform prices in the United States held flat in late August 2026, with FOB Los Angeles benchmarks maintaining a stable profile according to weekly assessment data. Early July saw quiet trading and routine buying, followed by a modest pullback in mid-July. By late August, Chloroform remained range-bound as balanced supply-demand fundamentals dominated market sentiment. Buyers and sellers generally accepted prevailing FOB Los Angeles levels, while monitoring downstream activity for signs of renewed demand. The absence of significant supply disruptions or urgent procurement kept the Chloroform market relatively calm through the end of August.

Demand patterns for Chloroform were mixed across downstream sectors. The refrigerant segment remained weak as HCFC-22 producers operated at muted rates after summer servicing demand had largely been booked earlier in the season, reducing incremental Chloroform consumption. Fluoropolymer demand provided modest support, with fluoropolymer resin output increasing 1.8% year on year in July, although the improvement was insufficient to materially tighten the market. Pharmaceutical-grade Chloroform demand remained steady under planned procurement schedules, while solvent and construction-chemical users in North America showed softer activity. Mexican solvent blenders reduced July call-offs by 2% amid sluggish construction-chemical sales, while overall U.S. chemical production remained essentially flat.

On the supply side, Chloroform production and input costs remained broadly stable. Chlorine output from salt electrolysis along the Gulf Coast continued at normal operating rates, while benign shale-gas economics helped keep chlorine cash costs contained. This stability prevented significant upward pressure on Chloroform production costs. Producer warehouses held approximately 2.5–3.0 weeks of inventory cover, ensuring adequate prompt availability and limiting the potential for short-term supply squeezes. Mid-month merger activity between major sellers temporarily paused some spot offers as companies aligned sales policies, creating slight merchant tightness. However, comfortable inventories and resilient logistics largely offset this effect, with no hurricane-related disruptions reported.

Looking ahead to September 2026, Chloroform prices are expected to face modest downward pressure as domestic availability remains comfortable and downstream procurement stays cautious. Pharmaceutical, refrigerant, and solvent demand is unlikely to provide sufficient momentum for a sustained price increase, while stable-to-softer methanol and chlorine costs could encourage competitive FOB offers. Merger-related withholding of discretionary spot volumes may periodically create tighter availability, but current inventory levels should limit the impact. A mild recovery could emerge later in the year as seasonal demand improves and the market gradually rebalances. However, Chloroform pricing will remain sensitive to feedstock movements, producer operating rates, and downstream purchasing conditions.